MONA S. ABDELLATEIF^1,*, NAGLAA M. HASSAN², MAHMOUD M. KAMEL², YOMNA M. EL-MELIGUI²

Oncology Research, Vol.32, No.3, pp. 577-584, 2024, DOI:10.32604/or.2023.043026 - 06 February 2024

Abstract Background: microRNA-34a (miR-34a) had been reported to have a diagnostic role in acute myeloid leukemia (AML). However, its value in the bone marrow (BM) of AML patients, in addition to its role in response to therapy is still unclear. The current study was designed to assess the diagnostic, prognostic, and predictive significance of miR-34a in the BM of AML patients. Methods: The miR-34a was assessed in BM aspirate of 82 AML patients in relation to 12 normal control subjects using qRT-PCR. The data were assessed for correlation with the relevant clinical criteria, response to therapy,… More >

ZHANSHU LIU¹, XI HUANG^2,*

BIOCELL, Vol.47, No.3, pp. 593-605, 2023, DOI:10.32604/biocell.2023.024148 - 03 January 2023

Abstract Purpose: Iron metabolism maintains the balance between iron absorption and excretion. Abnormal iron metabolism can cause numerous diseases, including tumor. This study determined the iron metabolism-related genes (IMRGs) signature that can predict the prognosis of acute myeloid leukemia (AML). The roles of these genes in the immune microenvironment were also explored. Methods: A total of 514 IMRGs were downloaded from the Molecular Characteristics Database (MSigDB). IMRGs related to AML prognosis were identified using Cox regression and LASSO analyses and were used to construct the risk score model. AML patients were stratified into high-risk groups (cluster 1)… More >

K. Venkatesh^1,*, S. Pasupathy¹, S. P. Raja²

Intelligent Automation & Soft Computing, Vol.36, No.1, pp. 543-560, 2023, DOI:10.32604/iasc.2023.030701 - 29 September 2022

Abstract The evolution of bone marrow morphology is necessary in Acute Myeloid Leukemia (AML) prediction. It takes an enormous number of times to analyze with the standardization and inter-observer variability. Here, we proposed a novel AML detection model using a Deep Convolutional Neural Network (D-CNN). The proposed Faster R-CNN (Faster Region-Based CNN) models are trained with Morphological Dataset. The proposed Faster R-CNN model is trained using the augmented dataset. For overcoming the Imbalanced Data problem, data augmentation techniques are imposed. The Faster R-CNN performance was compared with existing transfer learning techniques. The results show that the More >

PENG YANG^1,*, ZHIYING ZOU¹, XULING GAO²

BIOCELL, Vol.46, No.1, pp. 207-218, 2022, DOI:10.32604/biocell.2021.014728 - 29 September 2021

Abstract Recent studies have shown that the microtubule disrupting protein Stathmin 1 (STMN1) is differentially expressed in AML patients and healthy control. The aim of this study was to explore the effects and molecular mechanism of STMN1 in AML. Here, the expression of STMN1 in peripheral blood cells (PBMCs) and bone marrow of AML patients and healthy volunteers was detected by RT-PCR and Western blot. STMN1 expression was regulated by transfected with STMN1 overexpressed plasmid or shRNA in two human leukemia cell lines K562 and HL60. Cell proliferation was examined by CCK8 and Edu staining. Annexin V… More >

QIANSHAN TAO^#, QING ZHANG^#, HUIPING WANG, HAO XIAO, MEI ZHOU, LINLIN LIU, HUI QIN, JIYU WANG, FURUN AN, ZHIMIN ZHAI^*, YI DONG^*

BIOCELL, Vol.46, No.1, pp. 159-169, 2022, DOI:10.32604/biocell.2021.014139 - 29 September 2021

Abstract Acute myeloid leukemia (AML) is regarded as a stem cell disease. However, no one unique marker is expressed on leukemia stem cells (LSC) but not on leukemic blasts nor normal hematopoietic stem cells (HSC). CD34⁺ CD38- with or without CD123 or CD44 subpopulations are immunophenotypically defined as putative LSC fractions in AML. Nevertheless, markers that can be effectively and simply held responsible for the intrinsical heterogeneity of LSC is still unclear. In the present study, we examined the frequency of three different LSC subtypes (CD34⁺ CD38^-, CD34⁺ CD38^- CD123⁺ , CD34⁺ CD38^- CD44⁺ ) in AML at diagnosis. We then… More >

MESFER AL SHAHRANI^1,2,*, PRASANNA RAJAGOPALAN^1,2, MOHAMMAD ABOHASSAN¹, MOHAMMAD ALSHAHRANI¹, YASSER ALRAEY¹, REEM M. GAHTANI¹, SURESH RADHAKRISHNAN³, KHLOOD DAGREERY⁴

Oncology Research, Vol.29, No.3, pp. 149-157, 2021, DOI:10.32604/or.2022.03539 - 01 August 2022

Abstract Estrogen receptor (ER) α is expressed in a subset of patient-derived acute myeloid leukemia (AML) cells, whereas Akt is predominantly expressed in most types of AML. Targeting AML with dual inhibitors is a novel approach to combat the disease. Herein, we examined a novel small molecule, 3-(4-isopropyl) benzylidene-8-ethoxy,6- methyl, chroman-4-one (SBL-060), capable of targeting AML cells by inhibiting ERα and Akt kinase. The chemical properties of SBL-060 were identified by proton nuclear magnetic resonance (¹ H-NMR), ¹³C-NMR, and mass spectroscopy. In silico docking was performed using an automated protocol with AutoDock-VINA. THP-1 and HL-60 cell lines were… More >

HONG ZHOU^1,*, XIAOFENG JIA^1,2, FAN YANG¹

BIOCELL, Vol.45, No.3, pp. 711-722, 2021, DOI:10.32604/biocell.2021.014193 - 03 March 2021

Abstract Uncontrolled proliferation is a hallmark of cancer cells, yet the molecular mechanisms that contribute to this proliferation are unclear. Therapeutic treatment of cancer is suboptimal in many cases, with no accurate index by which to evaluate the success of treatment or patient prognosis. In this study, we explored the protein levels of nuclear phosphoeIF4E in acute myeloid leukemia (AML) cell lines and primary leukemia samples by Western blot and immunofluorescence and as well analyzed transcriptomes by RNA-seq. We found nuclear phospho-eIF4E, an exporter of oncogenic mRNAs, to be abundant in AML. Further, nuclear phospho-eIF4E abundance More >

Nikhil Gadewal^*1, Rohit Kumar^†1, Swapnil Aher^†, Anagha Gardane^†, Tarang Gaur^†, Ashok K. Varma^*‡§, Navin Khattry^¶, Syed K. Hasan^†§¶

Oncology Research, Vol.28, No.3, pp. 321-330, 2020, DOI:10.3727/096504020X15816752427321

Abstract Acute myeloid leukemia (AML) with NPM1 mutation is a disease driving genetic alteration with good prognosis. Although it has been suggested that NPM1 mutation induces chemosensitivity in leukemic cells, the underlying cause for the better survival of NPM1 mutated patients is still not clear. Mutant NPM1 AML has a unique microRNA and their target gene (mRNA) signature compared to wild-type NPM1. Dynamic regulation of miRNA–mRNA has been reported to influence the prognostic outcome. In the present study, in silico expression data of miRNA and mRNA in AML patients was retrieved from genome data commons, and differentially expressed miRNA… More >

Yun Qin^*, Yu Wang^†‡§, Dongbo Liu^¶

Oncology Research, Vol.28, No.4, pp. 357-369, 2020, DOI:10.3727/096504020X15844389264424

Abstract It has been reported that kindlin-3 expression is closely associated with progression of many cancers and microRNA (miRNA) processing. However, the effects and precise mechanisms of kindlin-3 in acute myeloid leukemia (AML) have not been well clarified. Our study aimed to explore the interaction between kindlin-3 and miR-4792 in AML. In our study, we found that the expression of kindlin-3 was dramatically increased in AML samples and cell lines, and the miR-4792 level was significantly downregulated. Interestingly, the low miR-4792 level was closely associated with upregulated kindlin-3 expression in AML samples. Moreover, introduction of miR-4792 More >

Hossam Kamli^*, Gaffar S. Zaman^*, Ahmad Shaikh^*, Abdullah A. Mobarki^†, Prasanna Rajagopalan^*‡

Oncology Research, Vol.28, No.9, pp. 899-911, 2020, DOI:10.3727/096504021X16281573507558

Abstract Inhibition of the dihydroorotate dehydrogenase (DHODH) has been successful at the preclinical level in controlling myeloid leukemia. However, poor clinical trials warrant the search for new potent DHODH inhibitors. Herein we present a novel DHODH inhibitor SBL-105 effective against myeloid leukemia. Chemical characteristics were identified by ¹ H NMR, ¹³C NMR, and mass spectroscopy. Virtual docking and molecular dynamic simulation analysis were performed using the automated protocol with AutoDock-VINA, GROMACS program. Human-recombinant (rh) DHODH was used for enzyme inhibition study. THP-1, TF-1, HL-60, and SKM-1 cell lines were used. MTT assay was used to assess cell… More >